

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA
NEWS	41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	43	Jun 06	PASCAL enhanced with additional data
NEWS	44	Jun 20	2003 edition of the FSTA Thesaurus is now available

NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:17:49 ON 03 JUL 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:17:54 ON 03 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUL 2003 HIGHEST RN 541497-70-5

DICTIONARY FILE UPDATES: 2 JUL 2003 HIGHEST RN 541497-70-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 'gly-rop-arg'/sqsfp

ROP IS NOT A VALID 3 LETTER AMINO ACID SYMBOL

=> s 'gly-pro-arg'/sqsfp

L1 1971656 'GLY-PRO-ARG'/SQSFP

<-----User Break----->

SEARCH ENDED BY USER

L1 HAS NO ANSWERS

=> s 'gly-pro-arg'/sqefp

```
      150 'GLY''PRO''ARG'/SQEFP
1449 SQL=3
L2      150 'GLY-PRO-ARG'/SQEFP
      ('GLY''PRO''ARG'/SQEFP AND SQL=3)
```

=> fil .search

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.90

8.11

FILE 'MEDLINE' ENTERED AT 13:20:25 ON 03 JUL 2003

FILE 'CAPLUS' ENTERED AT 13:20:25 ON 03 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:20:25 ON 03 JUL 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 13:20:25 ON 03 JUL 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:20:25 ON 03 JUL 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s 12

L3 94 L2

=> s 13 and (chelat? or ligand?)

L4 37 L3 AND (CHELAT? OR LIGAND?)

=> dup rem 14

PROCESSING COMPLETED FOR L4

L5 37 DUP REM L4 (0 DUPLICATES REMOVED)

=> d ibib ab hitstr 1-

YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE? Y/(N):y

LS ANSWER 1 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:435053 CAPLUS
DOCUMENT NUMBER: 119:12392
TITLE: Stabilization of radiopharmaceutical compositions
using hydrophilic 6-hydroxychromans
INVENTOR(S): Cyr, John E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of Appl.
No. PCT/US01/50423.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003103899	A1	20030605	US 2002-131346	20020424
WO 2002060491	A2	20020808	WO 2001-US50423	20011024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2000-695360 A2 20001024
WO 2001-US50423 A2 20011024
US 2000-694992 A1 20001024
US 2000-695494 A1 20001024

AB A compn. comprising a peptide or non-peptide radiopharmaceutical precursor and a stabilizing amt. of a hydrophilic 6-hydroxychroman deriv., e.g., 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), is described. A kit comprising a sealed vial contg. a predetd. quantity of

a radiopharmaceutical precursor and a stabilizing amt. of a hydrophilic 6-hydroxychroman deriv. is also described. For example, Trolox increased the radiolabeling yield and the stability of 99mTc depreotide prepd. from the kit.


IT 445311-35-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (stabilization of radiopharmaceutical precursors by hydrophilic hydroxychromans)

RN 445311-35-3 CAPLUS
CN L-Cysteineamide, N6-[N2,N6-bis(N-acetyl-L-threonyl-L-lysyl-L-prolyl-L-arginylglycylglycyl)-L-lysyl]-L-lysylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

LS ANSWER 1 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



LS ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:435053 CAPLUS
DOCUMENT NUMBER: 119:12392
TITLE: Stabilization of radiopharmaceutical compositions
using hydrophilic thioethers and hydrophilic 6-hydroxychromans
INVENTOR(S): Cyr, John E.; Pearson, Daniel A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of Appl.
No. PCT/US01/50423.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003103895	A1	20030605	US 2002-131546	20020424
WO 2002060491	A2	20020808	WO 2001-US50423	20011024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2000-695494 A2 20001024
WO 2001-US50423 A2 20011024
US 2000-694992 A1 20001024
US 2000-695360 A1 20001024

AB A compn. contg. a peptide or non-peptide radiopharmaceutical precursor and a stabilizing amt. of a mixt. of a hydrophilic thioether and a hydrophilic

6-hydroxychroman deriv. is described. The thioether is selected from, e.g., methionine, ethionine, 3-(methylthio)propionaldehyde, 2-(ethylthio)ethylamine, buthionine, S-methyl-cysteine, and methioninol. The hydrophilic 6-hydroxychroman used is, e.g., 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid or 6-hydroxy-2,5,7,8-tetramethylchroman-2-glucosamine. A kit comprising a sealed vial contg.

a predetd. quantity of a radiopharmaceutical precursor and a stabilizing amt. of a mixt. of a hydrophilic thioether and a hydrophilic 6-hydroxychroman deriv. is also described. For example, the combination of L-methionine and Trolox increased the radiolabeling yield and the stability of 99mTc depreotide prepd. from the kit.


IT 445311-35-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (stabilization of radiopharmaceutical precursors by hydrophilic thioethers and hydrophilic 6-hydroxychromans)

RN 445311-35-3 CAPLUS
CN L-Cysteineamide, N6-[N2,N6-bis(N-acetyl-L-threonyl-L-lysyl-L-prolyl-L-arginylglycylglycyl)-L-lysyl]-L-lysylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

LS ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B




L5 ANSWER 3 OF 37 USPATFULL
 ACCESSION NUMBER: 2003:105799 USPATFULL
 TITLE: Stabilization of radiopharmaceutical compositions
 using hydrophilic thioethers
 INVENTOR(S): Cyr, John E., Bedford, NH, UNITED STATES
 Pearson, Daniel A., Bedford, NH, UNITED STATES

NUMBER	KIND	DATE
US 2003072770	A1	20030417
US 2002-131543	A1	20020424 (10)

PATENT INFORMATION: US 2003072770
 APPLICATION INFO.: US 2002-131543
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-694992, filed on 24 Oct 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US0423, filed on 24 Oct 2001, PENDING
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FISH & RICHARDSON P.C., 45 ROCKEFELLER PLAZA, SUITE 2800, NEW YORK, NY, 10111
 NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1361
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic thioether.
 IT 445311-35-3
 (stabilization of radiopharmaceutical compns. using hydrophilic thioethers)
 RN 445311-35-3 USPATFULL
 CN L-Cysteinamide, N6-(N2,N6-bis(N-acetyl-L-threonyl-L-lysyl-L-prolyl-L-arginylglycylglycyl)-L-lysyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


PAGE 1-A



L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:159727 CAPLUS
 DOCUMENT NUMBER: 138:331165
 TITLE: Quantitative Analysis of Permeation Peptide Complexes Labeled with Technetium-99m: Chiral and Sequence-Specific Effects on Net Cell Uptake
 AUTHOR(S): Gammon, Seth T.; Villalobos, Victor M.; Prior, Julie L.; Sharma, Vijay; Piwnicka-Worms, David
 CORPORATE SOURCE: Department of Molecular Biology and Pharmacology, Washington University Medical School, Molecular Imaging Center Mallinckrodt Institute of Radiology, Saint Louis, MO, 63110, USA
 SOURCE: Bioconjugate Chemistry (2003), 14(2), 368-376
 CODEN: BCCHE; ISSN: 1043-1802
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB This study investigated sequence-specific cell uptake characteristics of Tat basic domain and related permeation peptides with an emphasis on residue chirality, length, and modified side chains. Effects on cell permeation of defined basic domain sequences within a library of 42 different peptides were evaluated using transport of radiolabeled peptides into human Jurkat leukemia cells. All other factors being equal, when the chirality of the peptide sequence was changed from L to D, uptake values increased up to 13-fold. Control expts. showed that the quant. difference in uptake could not be attributed to increased decompn. of an L- vs. a D-peptide by cellular or serum proteases. Furthermore, length, sequence, and type of chelation domain impacted peptide uptake into cells. The highest level of uptake was found with the following peptides: (23) D-Tat-Orn [Ac-rkkrr-orn-rrr-AHA-kgc-amide] and (33) D-poly-Arg9 [Ac-rrrrrrrrr-AHA-kgc-amide]. The best of these peptide sequences could be employed as in vivo imaging and drug delivery agents to translocate substrates into cells.
 IT 518052-21-6D, reaction with biotin, technetium complexes
 518052-22-7D, reaction with biotin, technetium complexes
 518052-23-8D, reaction with biotin, technetium complexes
 518052-24-9D, reaction with biotin, technetium complexes
 RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chiral and sequence-specific effects in net cell uptake of peptide complexes labeled with Technetium-99m)
 RN 518052-21-6 CAPLUS
 CN D-Cysteinamide, N6-(D-arginyl-D-arginyl-D-alanyl-D-arginyl-D-arginyl-6-aminohexanoyl)-D-lysylglycyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L5 ANSWER 3 OF 37 USPATFULL (Continued)

PAGE 1-B




L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




RN 518052-22-7 CAPLUS
 CN D-Cysteinamide, N6-(D-alanyl-D-arginyl-D-arginyl-D-alanyl-D-alanyl-D-arginyl-D-arginyl-6-aminohexanoyl)-D-lysylglycyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B



RN 518052-23-8 CAPLUS
 CN D-Cysteinamide, N6-(D-alanyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-alanyl-D-arginyl-D-arginyl-6-aminohexanoyl)-D-lysylglycyl- (9CI) (CA

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B




RN 518052-24-9 CAPLUS
 CN D-Cysteinamide, N6-(D-arginyl-D-alanyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-alanyl-D-arginyl-D-arginyl-6-aminohexanoyl)-D-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.

PAGE 1-A




L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

[illegible]

L5 ANSWER 6 OF 37 USPATFULL (Continued)
lysyl]- (9CI) (CA INDEX NAME)
STRUCTURE DIAGRAM IS NOT AVAILABLE

STRUCTURE DIAGRAM IS NOT AVAILABLE

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19525924	19950704
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	2106	

```


      STRUCTURE DIAGRAM IS NOT AVAILABLE
IT  186148-77-GDP, gadolinium complexes
    (prep.n of cascade polymer complexes as medical contrast media)
RN  186148-77-6 USPATFULL
CN  L-lysineamide, 3,3',3'',3'''-tetrakis(3,3''',3''''',3''''')-[1,4,7,10-
    ethanediyl]undecane-1,4,7,10-tetrayl[tetraakis[2-oxo-2,1-
    ethanediyl]undecano-2,1-ethanediyloxy]nitrile-2,1-
    ethanediyl]octakis[N2,N6-bis-(N2,N6-bis-N[1-oxo-2,1,4,7,10-
    tri(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]glycyl]-L-

```


Absolute stereochemistry

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A





PAGE 1-B




L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
 REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-C

RN 187284-90-8 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-
 (.alpha.-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycyl
 lycyl]-L-lysyl]-L-lysyl]-L-lysyl]-L-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:816499 CAPLUS
 DOCUMENT NUMBER: 135:376735
 TITLE: Membrane-permeant peptide complexes for medical
 imaging, diagnostics, and pharmaceutical therapy
 INVENTOR(S): Pivnick-Worms, David
 PATENT ASSIGNEE(S): Washington University, USA
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082975	A2	20011108	WO 2001-US13179	20010424
WO 2001082975	A3	20020829		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CN, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1294409	A2	20030326	EP 2001-928805	20010424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-557465 A 20000425 WO 2001-US13179 W 20010424				
AB Methods and compns. for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.				
IT 371918-29-5				
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);				
USES (Uses) (membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy)				
RN 371918-29-5 CAPLUS				
CN D-Cysteineamide, N6-[N2-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-D-arginyl]-D-alanyl-D-alanyl-D-arginyl-D-arginyl-D-alanyl-D-alanyl-D-arginyl-D-arginyl-6-aminohexanoyl]-D-lysylglycyl- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B



L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



L5 ANSWER 10 OF 37 USPATFULL
 ACCESSION NUMBER: 2001:191246 USPATFULL
 TITLE: Method for synthesis of proteins
 INVENTOR(S): Tam, James P., Nashville, TN, United States
 PATENT ASSIGNEE(S): Vanderbilt University, Nashville, TN, United States
 (U.S. corporation)

NUMBER	KIND	DATE
US 6310180	B1	20011030
US 1995-492411		19950619 (8)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 1995-490932, filed on 16 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-263936, filed on 21 Jun 1994, now abandoned Continuation-in-part of Ser. No. US 1993-81412, filed on 21 Jun 1993, now patented, Pat. No. US 5589356

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Venkat, Jyothsna
 ASSISTANT EXAMINER: Garcia, Maurie E.
 LEGAL REPRESENTATIVE: Klauber & Jackson
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 37 Drawing Page(s)
 LINE COUNT: 3427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for peptide synthesis is disclosed that requires neither protecting groups nor activation of the C- α carboxyl groups. The method comprises ligating a first molecule to a second molecule by promoting the orthogonal coupling of the molecules to each other. In an aspect of this method, an acyl-type reaction occurs between the molecules. The method contemplates the joining of molecules of variant size to each other, as well as the coupling of multiple identical molecules. The invention also covers the ligation of unprotected peptide, proteins or nonpeptide segments to prepare therapeutic products

and synthetic vaccines with linear, circularized, or branched backbone structures, as well as the site-specific modification of peptides or proteins by lipidation and pegylation.

IT 162261-12-3P 163479-45-6P 163479-46-7P
 (method for synthesis of proteins)

RN 162261-12-3 USPATFULL

CN L-Alaninamide,

2-carboxy-4-thiazolidinecarbonyl-L-asparaginyl-L-threonyl-L-

asparaginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-isoleucyl-L-histidyl-L-isoleucyl-L-prolylglycyl-L-prolyl-L-arginyl-

(1.fwdarw.1'''''), (1'.fwdarw.1'''''), (1'''.fwdarw.1'''''), (1'''''.fwdarw.1''''')-tetraamide with N2,N6-di-L-lysyl-L-lysyl-.beta.-alanine (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 163479-45-6 USPATFULL

CN L-Alaninamide,

2-carboxy-4-thiazolidinecarbonyl-L-asparaginyl-L-threonyl-L-

asparaginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-isoleucyl-L-histidyl-L-isoleucyl-L-prolylglycyl-L-prolyl-L-arginyl-

1,1',1'',1''',1''''',1''''',1''''',1'''''-octaamide with

L5 ANSWER 10 OF 37 USPATFULL (Continued)

N2,N6-bis(N2,N6-di-L-lysyl-L-lysyl)-L-lysyl-.beta.-alanine (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 163479-46-7 USPATFULL

CN L-Arginine, N-[4-[(carboxymethylene)hydrazinol]benzoyl]-L-seryl-L-seryl-L-glutamyl-L-phenylalanyl-L-glutamyl-L-isoleucyl-L-histidylglycyl-L-prolyl-, 1,1',1'',1''',1''''',1''''',1''''',1'''''-octaamide with N2,N6-bis(N2,N6-di-L-lysyl-L-lysyl)-L-lysyl-.beta.-alanine (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

[illegible]

LS ANSWER 11 OF 37 USPATFULL (Continued)
lysyl)-, stereoisomer (9CI) (CA INDEX NAME)
STRUCTURE DIAGRAM IS NOT AVAILABLE

ANSWER 13 OF 37 USPATFULL
ACCESSION NUMBER: 2001.10522 USPATFULL
TITLE: Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes
INVENTOR(S): Schmitt-Willich, Heribert, Berlin, Germany, Federal Republic of
of Platzeck, Johannes, Berlin, Germany, Federal Republic of
Raduchel, Bernd, Berlin, Germany, Federal Republic of
Muhler, Andreas, Neuenhagen, Germany, Federal Republic of
Frenzel, Thomas, Berlin, Germany, Federal Republic of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6177060	B1	20010123
APPLICATION INFO:	US 1998-44254		19980319 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-674844, filed on 3 Jul 1996, now patented, Pat. No. US 5820849		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19525924	19950704
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan, P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1880	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cascade polymer complexes with at least 16 ions of an element of atomic numbers 20 to 29, 39, 42, 44 or 57-83, useful NMR or x-ray lymphography imaging.
IT 186148-77-6P
(prepn. of cascade polymer complexes as medical contrast media)
RN 186148-77-6 USPATFULL
CN L-Lysineamide, 3,3',3'',3''',3'''',3''''',3''''',3''''',[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayltetrakis[(2-oxo-2,1-ethanediyloxy(1-oxo-2,1-ethanediylnitridol)-2,1-ethanediylo)octakis(N2,N6-bis[N-(1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propylglycyl)-L-lyseyl]- (9CI) (CA INDEX NAME)]
STRUCTURE DIAGRAM IS NOT AVAILABLE
IT 186148-77-6DP, gadolinium complexes
(prepn. of cascade polymer complexes as medical contrast media)
RN 186148-77-6 USPATFULL
CN L-Lysineamide, 3,3',3'',3''',3'''',3''''',3''''',3''''',[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayltetrakis[(2-oxo-2,1-ethanediyloxy(1-oxo-2,1-ethanediylnitridol)-2,1-ethanediylo)octakis(N2,N6-bis[N-(1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propylglycyl)-L-lyseyl]- (9CI) (CA INDEX NAME)]
STRUCTURE DIAGRAM IS NOT AVAILABLE

U5 ANSWER 14 OF 37 USPATFULL
 ACCESSION NUMBER: 2000.174826 USPATFULL
 TITLE: Cascade polymer complexes, process for their
 production
 INVENTOR(S): and pharmaceutical agents containing said complexes
 Schmitt-Willich, Heribert, Berlin, Germany, Federal
 Republic of
 of Plattek, Johannes, Berlin, Germany, Federal Republic
 Raduchel, Bernd, Berlin, Germany, Federal Republic of
 Muhler, Andreas, Neuenhagen, Germany, Federal Republic
 of
 PATENT ASSIGNEE(S): Frenzel, Thomas, Berlin, Germany, Federal Republic of
 Schering Aktiengesellschaft, Germany, Federal Republic
 of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166200		20001226
APPLICATION INFO.:	US 1999-345807		19990702 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-46254, filed on 19 Mar 1998 which is a division of Ser. No. US 1996-674844, filed on 3 Jul 1996, now patented, Pat. No. US 5820849		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19525924	19950704
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Millen, White, Zelano, & Branigan, P.C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1904	
CLASS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Cascade polymer complexes that contain		

a) complexing ligands of general formula I

$$A--\{X--\{Y--\{Z--W--K_{sub.W} \cdot_{sub.Z} \cdot_{sub.Y} \} \cdot_{sub.X} \} \cdot_{sub.A} \quad (I).$$

A stands for a nitrogen-containing cascade nucleus of base multiplicity A .

X and Y, independently of one another, stand for a direct bond or a cascade reproduction unit of reproduction multiplicity x or y,

z and w , independently of one another, stand for a cascade reproduction unit of reproduction multiplicity z or w .

K stands for the radical of a complexing agent.

'a stands for numbers 2 to 12.

L5 ANSWER 15 OF 37 USPATFULL
ACCESSION NUMBER: 2000:157221 USPATFULL
TITLE: Nucleic acid transporter systems and methods of use
INVENTOR(S): Woo, Saeio L. C., Houston, TX, United States
Smith, Louis C., Houston, TX, United States
Cristiano, Richard J., Pearland, TX, United States
Gotchalk, Stephen, Houston, TX, United States
Sparrow, Jim, Houston, TX, United States
PATENT ASSIGNEE(S): Baylor College of Medicine, Houston, TX, United States
(U.S. CORPORATION)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150168		20001131
APPLICATION INFO.:	US 1995-460971		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-167641,		filed on 14 Dec 1993, now patented, Pat. No. US 6033884 which is a continuation-in-part of Ser. No. US 1992-855389, filed on 20 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US2725, filed on 19 Mar 1993
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brueca, John S.		
ASSISTANT EXAMINER:	Shibuya, Mark L.		
LEGAL REPRESENTATIVE:	Lyons & Lyons LLP		
NUMBER OF CLAIMS:	52		
EXEMPLARY CLAIM:	38		
NUMBER OF DRAWINGS:	51 Drawing Figure(s); 40 Drawing Page(s)		
LINE COUNT:	4249		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Nucleic acid transporter systems for delivery of nucleic acid to a cell.		

The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.

IT 154531-22-3P
(prepn. of, for use in DNA transporter system for genetic transformation and gene therapy)

RN 154531-22-3 USPATFULL
 CN L-Lysine, N-[1-oxo-3-[[2-[[[L-tyrosyl-N6-[26-[[4-O-.beta.-D-

galactopyranosyl-.beta.-D-galactopyranosyl)oxy]-14-[[[6-{2-[(4-O-.beta.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]-1,1-bis[(4-O-.beta.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxymethyl]ethyl]amino)-6-oxohexyl]amino]carbonyl]-25,25-bis(4-O-.beta.-D-galactopyranosyl)-5,13,17,24-tetraazabicycloocta-1-vinyl-L-lyxyl-L-prolxyl-L-thiaetha-5,13,17,24-tetraazabicycloocta-1-vinyl-L-lyxyl-L-prolxyl-L-thiaetha

alanyl-L-lysyl-L-alanyl-L-lysyl|aminoethyl|dithiolpropyl)-L-tyrosyl-N6-(
3-carboxy-1-oxopropyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-
threonyl-L-alanyl-L-1-furyl)-amide with glycyl-L-tyrosyl-L-seryl-L-
threonyl-L-prolyl-L-prolyl-L-lysyl-L-lysyl-L-lysyl-L-arginyl-L-lysyl-L-
valyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-prolinamide (9CI) (CA
INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

x, y, z and w, independently of one another, stand for numbers 1 to 4, provides that at least two reproduction units are different and that the product of the multiplicities,

$16 \cdot l_{\text{toreq.a}} \cdot \text{multidot.x} \cdot \text{multidot.y} \cdot \text{multidot.z} \cdot \text{multidot.w} \cdot l_{\text{toreq.64}}$

holds true,

b) at least 16 ions of an element of atomic numbers 20 to 29, 39, 42, or 57-83,

c) optionally cations of inorganic and/or organic bases, amino acids or amino acid amides as well as

d) optionally acylated terminal amino groups are valuable compounds for diagnosis and therapy.

IT 186148-77-6P
(prepn. of cascade polymer complexes as medical contrast media)

RN	186148-77-6	USPATFULL
CN	L-Lysinamide, 3,3',3'',3''',3'''',3'''''-[2,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayltetrakis[[(2-oxo-2,1-ethanediyl)oxy(1-oxo-2,1-ethanediylyl)nitrido]-2,1-ethanediyl]octakis[N ₂ ,N ₆ -bis[N ₂ ,N ₆ -bis[N-(1-oxo-2-{4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl}propyl)glycyl]eyl]]- (9CI) (CA INDEX NAME)	


STRUCTURE DIAGRAM IS NOT AVAILABLE

IT 186148-77-6DP, gadolinium complexes
(prepn. of cascade polymer complexes as medical contrast media)


[illegible]

STRUCTURE DIAGRAM IS NOT AVAILABLE

PAGE 1-A



PAGE 1-B



STRUCTURE DIAGRAM IS NOT AVAILABLE

x, y, z and w, independently of one another, stand for numbers 1 to 4.


STRUCTURE DIAGRAM IS NOT AVAILABLE
RN 180514-62-9 USPATFULL

L5 ANSWER 20 OF 37 USPATFULL (Continued)
CN Glycinamide, L-cysteinylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-lysyl-L-threonylglycyl-L-lysyl-L-prolylglycyl-L-leucyl-L-asparaginylglycyl-L-glutamyl-L-lysylglycyl-L-glutamyl-L-lysylglycyl-L- α -glutamyl-L-lysylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-(1',fwdarw.1'''), (1',fwdarw.3'''), (1',fwdarw.4''')-tris(thioether) with N2-[6-[[N-(mercaptoacetyl)- β -alanyl- β -alanyl-N6-[N-(mercaptoacetyl)- β -alanyl- β -alanyl]-L-lysyl-N6-[N-(mercaptoacetyl)- β -alanyl- β -alanyl]-L-lysylamino]-1-oxohexyl]-oxopentylamino]-1-oxohexyl]-L-lysyl-L-tyrosinamide (9CI) (CA INDEX NAME)
STRUCTURE DIAGRAM IS NOT AVAILABLE
RN 180584-60-5 USPATFULL
CN Glycinamide, L-cysteinylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-lysyl-L-threonylglycyl-L-lysyl-L-prolylglycyl-L-leucyl-L-asparaginylglycyl-L-glutamyl-L-lysylglycyl-L-glutamyl-L-lysylglycyl-L- α -glutamyl-L-lysylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-(1',fwdarw.1'''), (1',fwdarw.3'''), (1',fwdarw.4''')-tris(thioether) with N-(mercaptoacetyl)- β -alanyl- β -alanyl-N6-[N-(mercaptoacetyl)- β -alanyl- β -alanyl]-L-lysyl-N6-[N-(mercaptoacetyl)- β -alanyl- β -alanyl]-L-lysyl-L-tyrosinamide (9CI) (CA INDEX NAME)
STRUCTURE DIAGRAM IS NOT AVAILABLE


L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:378602 CAPLUS
DOCUMENT NUMBER: 129:136399
TITLE: Chemoenzymic synthesis of dendritic sialyl Lewis^x
AUTHOR(S): Palcic, Monica M.; Li, Hong; Zanini, Diana; Bhella, Resham S.; Roy, Rene
CORPORATE SOURCE: Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Can.
SOURCE: Carbohydrate Research (1998), Volume Date 1997, 305(3-4), 433-442
CODEN: CRBRAT; ISSN: 0008-6215
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Traditional structure activity relationship studies (SAR) have led to the development of numerous sialyl Lewis^x analogs in the search for potential antiinflammatory agents. However, these methods do not take into account cluster or multivalent effects. Reported herein is the chemoenzymic synthesis of di-, tetra-, and octa-valent slex ligands scaffolded on dendrimers. Hypervalent L-lysine cores with covalently attached 2-acetamido-2-deoxy-D-glucose (N-acetylglucosamine, GlcNAc) residues were chem. prepd. and enzymically transformed into slex-contg. dendrimers so that multivalency, and its role in selectin-slex interactions may be evaluated. This work constitutes another successful enzymic synthesis of slex and represents the first example of GlcNAc elongation on a synthetic dendrimer scaffold. These slex dendrimers are currently being investigated as selectin antagonists.
IT RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
RN 210472-90-5 CAPLUS
CN β -Alanine, N2,N6-bis[N2,N6-bis[N-[[[O-(N-acetyl- α -neuraminyloxy)]-(2,fwdarw.3)-O- β -D-galactopyranosyl-(1,fwdarw.4)-O-(6-deoxy- α -L-galactopyranosyl)]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 187988-44-9P 187988-45-0P 188039-95-4P 188132-41-4P 210471-92-4P
RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(chemoenzymic synthesis of dendritic sialyl Lewis^x)
RN 187988-44-9 CAPLUS
CN β -Alanine, N2,N6-bis[N-[[[2-(acetylamino)-2-deoxy-4-O- β -D-galactopyranosyl]- β -D-glucopyranosyl]thio]acetyl]glycylglycyl]-L-lysyl- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




RN 187988-45-0 CAPLUS
CN β -Alanine, N2,N6-bis[N2,N6-bis[N-[[[2-(acetylamino)-2-deoxy-4-O- β -D-galactopyranosyl]- β -D-glucopyranosyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



RN 188039-95-4 CAPLUS

CN .beta.-Alanine,

N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[2-(acetylamino)-2-deoxy-

4-O-.beta.-D-galactopyranosyl-.beta.-D-glucopyranosyl]thio]acetyl]glycylglycyl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 188132-41-4 CAPLUS

CN .beta.-Alanine,

N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[2-(acetylamino)-2-deoxy-

.beta.-D-glucopyranosyl]thio]acetyl]glycylglycyl-L-lysyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 210471-92-4 CAPLUS

CN .beta.-Alanine,

N2,N6-bis[N2,N6-bis[N-[[[O-(N-acetyl-.alpha.-neuraminoacyl)-

L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:165206 CAPLUS

DOCUMENT NUMBER: 126:154428

TITLE: Process for the identification of proteolytic activities and/or inhibitors thereof

INVENTOR(S): Fassina, Giorgio; Corti, Angelo

PATENT ASSIGNEE(S): Tecnogen S.C.P.A., Italy

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXMDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 751225	A1	19970102	EP 1996-114931	19911014
EP 751225	B1	20010328		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 481930	A2	19920422	EP 1991-830428	19911014
EP 481930	A3	19930630		
EP 481930	B1	19970618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 154609	E	19970715	AT 1991-830428	19911014
AT 200107	E	20010415	AT 1996-114931	19911014
PRIORITY APPLN. INFO.:			IT 1990-48365	A 19901015
			IT 1991-RM261	A 19910415
			EP 1991-830428	A3 19911014
			IT 1991-RO261	19910415

AB This invention relates to a process for the identification of proteolytic activities or of activities that inhibit proteolytic activities, particularly of endothelin and/or of TNF, esp. in biol. fluids, fermm. broths, conditioned culture soils, cell exts., and plant exts. As an example, the process can use a fragment of proendothelin as substrate as well as a ligand comprising amino acid sequences that are hydropathically complementary to the fragment of proendothelin.

143226-64-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(detn. of proendothelin- and TNF-specific proteolytic activities and their inhibitors)

RN 143226-64-6 CAPLUS

CN Glycine, N2,N6-bis[N2,N6-bis[N2,N6-bis(glycylglycylglycyl)-L-lysyl-L-arginyl]-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

(2.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]thio]acetyl]glycylglycyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS


FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

PAGE 1-A



PAGE 1-B



PAGE 2-A

The chemical structure is a complex molecule with the following features:

- A guanidino group on the left: $\text{H}_2\text{N}-\text{C}(\text{NH})=\text{NH}-$
- A propyl chain: $(\text{CH}_2)_3-$
- A thioether linkage: $-\text{S}-$
- A chiral center: A carbon atom bonded to a methyl group (represented by a vertical line), a hydrogen atom (represented by a horizontal line), and a thioether group.
- A disulfide bridge: $-\text{S}-$
- A tetramethylene chain: $(\text{CH}_2)_4-$
- An amide bond: $-\text{NH}-\text{C}(=\text{O})-$
- A carboxylic acid group: $-\text{C}(=\text{O})\text{OH}$

CC(=O)CN(C)CNC

Chemical structure of a poly(amide-ester) copolymer. The structure shows a repeating unit with amide and ester linkages. A side chain is attached via a sulfur atom to a methylene group (CH₂)₄, which is further connected to a thioether linkage (-S-) and a thioamide group (-C(=S)NH-R).

OTHER SOURCE(S): MARPAT 126-115166 (continued)

AB N-contg., complex-forming ligands attached to cascade polymers, which can bind, gtorep.16 transition element or lanthanide ions or org. cations per polymer mol., are useful as contrast agents for NMR or radiog.

diagnosis. Thus, a protected trimelic acid hexakis(2-aminoethyl)triamide was condensed with a protected N.alpha.,N.epsilon.-bis(1lysyl)lysine to produce a protected 24-polyamine, trimelic acid hexakis(2-tri(lysylamino)ethyl)triamide. This compd. in turn was condensed with 10-(4-carboxy-1-methyl-1,4,7,10-tetraazacyclododecane) (prepn. given), and the resulting cascade polyamide was complexed with Gd3+ to provide a contrast agent. This complex, injected i.v. into rats, showed relatively little diffusion into the interstitial space, and thus was useful for imaging the blood pool.

IT	giving rnf blood pool. 186248-77-69 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prep.n of cascade polymer complexes as medical contrast media)
RN	186148-77-6 CAPLUS
CN	L-Lysineamide, 3,3',3'',3''',3'''',3''''',3''''',3''''''-[1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetrayltetrakis[(2-oxo-2,1-ethenediyl)oxy(1-oxo-2,1-ethenediyl)nitrilodi-2,1-ethenediyl]octakis[N₂,N₆-bis[N₂,N₆-bis[N-yl]oxy-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]glycyl]-L-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 186148-77-6DP, gadolinium complexes
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of cascade polymer complexes as medical contrast media)

RN	186148-77-6	CAPLUS
CN	L-Lysinamide, 3,3',3'',3''',3'''',3''''',3''''',3''''',3'''''-[1,4,7,10-	

tetraazacyclododecane-1,4,7,10-tetrayltetrakis[(2-oxo-2,1-ethanediyl oxy(1-oxo-2,1-ethanediyl)nitrilodi-2,1-ethanediyl)]octakis[N2,N6-bis[N2,N6-bis[N-1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propylglycyl]-L-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ACCESSION NUMBER: 1997:113886 CAPIUS
DOCUMENT NUMBER: 126:115166
TITLE: Cascade polymer complexes for use in medical
diagnostics
INVENTOR(S): Schmitt-Willich, Heribert; Platzek, Johannes;
Raduechel, Bernd; Muehler, Andreas; Prenzel, Thomas
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: Ger. Offen., 43 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19525924	A1	19970109	DE 1995-19525924	19950704
CA 2225959	AA	19970123	CA 1996-2225959	19960620
WO 9702051	A2	19970123	WO 1996-EP2671	19960620
WO 9702051	A3	19970123		
W: AU, BG, BR, BY, CA, CN, CZ, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, VN				
RN: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9663586	A1	19970205	AU 1996-63586	19960620
AU 713470	B2	19991202		
EP 836485	A2	19980422	EP 1996-922859	19960620
EP 836485	B1	20020724		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1189779	A	19980805	CN 1996-195200	19960620
CN 1079679	B	20020227		
BR 9609478	A	19990525	BR 1996-9478	19960620
JP 11510834	T2	19990921	JP 1996-504756	19960620
NZ 312127	A	20000128	NZ 1996-312127	19960620
RU 2165501	C2	20010510	RU 1998-101903	19960620
AT 220924	E	20020815	AT 1996-922859	19960620
ES 2177792	T3	20021216	ES 1996-922859	19960620
US 5820849	A	19981013	US 1996-674844	19960703
ZA 9605686	A	19970124	ZA 1996-5686	19960704
WO 9800002	A	19980304	NO 1998-2	19980102
US 6063361	A	20000515	US 1998-40364	19980318
US 6177060	B1	20010123	US 1998-44254	19980319
HK 1013915	A1	20020802	HK 1998-112506	19981130
US 6166200	A	20001226	US 1999-345807	19990702
AU 9947393	A1	19991125	AU 1999-47393	19990906
AU 726604	B2	20001116		
US 6176059	B1	20020724	US 2000-620989	20000720
CN 1377881	A	20021106	CN 2001-142101	20010911
US 2002187101	A1	20021212	US 2002-138651	20020506
PRIORITY APPLN. INFO.:			DE 1995-19525924	A 19950704
			AU 1996-63586	A3 19960620
			WO 1996-EP2671	W 19960620
			US 1996-674844	A1 19960703
			US 1998-44254	A3 19980319
			US 2000-620989	A1 20000720

ACCESSION NUMBER: 97:96838 USPATFULL
TITLE: Peptide-chelator conjugates
INVENTOR(S): Goodbody, Anne, Toronto, Canada
Pollak, Alfred, Toronto, Canada
PATENT ASSIGNEE(S): Resolution Pharmaceuticals Inc., Mississauga, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679642		19971021
APPLICATION INFO.:	US 1996-713484		19960913 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-202178,		filed on 25 Feb 1994, now patented, Pat. No. US 5569745
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hutzell, Paula K.		
ASSISTANT EXAMINER:	Prickrell, Benet		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
LINE COUNT:	575		

AB Peptide-chelator conjugates are provided that when labelled with a traceable metal are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin while the chelator component serves as a labelling site for metals, in particular, radionuclides.

metals
such as technetium-99m.

IT 169048-14-ODP, chelates
(peptide-chelator conjugates for diagnostic imaging)

```


RN      169048-14-0  USPATFULL
CN      L-Alanine, N-[6-[2-[S-[(acetylamino)methyl]-N-(N-(2-pyridinylcarbonyl)-L-
seryl]-L-cysteiny]hydrazino]-N-[N-[N2-[1-[1-[N2-(N-formyl-L-threonyl)-L-
lysyl]-L-prolyl]-L-prolyl]-L-arganyl]glycyl]-L-norleucyl]- (SCI) (CA
INDEX NAME

```


Absolute stereochemistry.

L5 ANSWER 24 OF 37 USPATTFULL (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 25 OF 37 USPATTFULL (Continued)

PAGE 1-A



PAGE 1-B



L5 ANSWER 25 OF 37 USPATTFULL

ACCESSION NUMBER: 97:47502 USPATTFULL
 TITLE: Selectively cleavable linkers based on iminodiacetic acid esters for solid phase peptide synthesis
 INVENTOR(S): Lebl, Michal, Oro Valley, AZ, United States
 Krchnak, Viktor, Oro Valley, AZ, United States
 Kocis, Petr, Oro Valley, AZ, United States
 Lam, Kit S., Tucson, AZ, United States
 PATENT ASSIGNEE(S): Selectide Corporation, Tucson, AZ, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5635598 19970603
 APPLICATION INFO.: US 1994-263289 19940621 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-81997, filed on 23 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-80388, filed on 21 Jun 1993, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Lukton, David
 LEGAL REPRESENTATIVE: Pennie & Edmonds
 NUMBER OF CLAIMS: 47
 EXEMPLARY CLAIMS: 1
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 2349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to linkers based on ester bond linkages, especially iminodiacetic acid ester bond linkages, for use in solid phase peptide synthesis. In particular, the invention is directed to cleavable linkers that can release peptide from the solid phase support under relatively mild conditions by formation of a diketopiperazine or other cyclic structure, such that the cyclic structure remains on the solid phase support, and, in a second cleavage,

under more stringent conditions of high pH. The invention is further directed to solid phase supports prepared with multiple cleavable linkages, including a linker that is cleaved by formation of a cyclic product. One such second linker is an ester of hydroxymethylbenzoic acid, or esters formed by carboxy groups of aspartic or glutamic acid.

IT 167628-87-7DP, resin-bound
 (selectively cleavable linkers based on iminodiacetic acid esters for solid phase peptide synthesis)

RN 167628-87-7 USPATTFULL


CN L-lysine.

N-[(1,1-dimethylethoxy)carbonyl]glycyl-N-[2-[3-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tryptophylglycyl]aminopropoxy]-2-oxoethyl]glycyl-N-[2-[3-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tryptophyl-L-valylglycyl]aminopropoxy]-2-oxoethyl]glycyl-N6-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tryptophyl-L-valyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 25 OF 37 USPATTFULL (Continued)

PAGE 2-A




PAGE 2-B




L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

H₂N—


PAGE 1-B




L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-C



PAGE 2-A



PAGE 2-B




RN 189076-17-3 CAPLUS

CN L-Cysteine, L-lysylglycyl-L-glutamyl-L-lysyl-N6-(L-lysylglycyl-L-glutamyl)-L-lysyl-N6-(L-lysylglycyl-L-glutamyl)-L-lysyl-L-α-glutamyl-N6-(L-lysylglycyl-L-glutamyl)-L-lysylglycyl- (9CI) (CA INDEX NAME)

L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



PAGE 2-B



L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:145739 CAPLUS
 DOCUMENT NUMBER: 128:292317
 TITLE: Glycodendrimers as novel biochromatography adsorbents
 AUTHOR(S): Page, Daniel; Roy, Rene
 CORPORATE SOURCE: Department of Chemistry, University of Ottawa,
 Ottawa,
 ON, K1N 6N5, Can.

SOURCE: International Journal of Bio-Chromatography (1997),
 3(3), 231-244
 CODEN: IJOBSQ; ISSN: 1068-0659
 PUBLISHER: Harwood Academic Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Synthetic multivalent glycoconjugates ending with mannopyranoside
 residues

were evaluated as ligands for the phytohemagglutinins from Con A
 (Con A) and Pisum sativum using enzyme-linked lectin assays (ELLA) and
 turbidimetric analyses. The relative affinity of the neoglycoconjugates,
 together with few ref. monosaccharides, were detd. by solid-phase
 inhibition assays using yeast mannan as coating antigen and
 peroxidase-labeled lectins. The ability of these ligands to
 selectively ppt. a mannose-binding protein (Con A) from a crude mixt. was
 also demonstrated using PAGE (SDS-PAGE). These multivalent
 glycoconjugates (glycodendrimers) were shown to constitute novel
 biochromatog. materials of high affinity for the isolation of
 carbohydrate-binding proteins.

IT 187147-04-2 187147-06-4 187147-06-4B,
 oligomeric 187284-57-7
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BSU
 (Biological study, unclassified); NUU (Other use, unclassified); ANST
 (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (glycodendrimers as novel biochromatog. adsorbents)


RN 187147-04-2 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N-[[[3-[[4-(.alpha.-D-
 mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-
 lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B




RN 187147-06-4 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N-[[[3-[[4-(.alpha.-D-
 mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-
 lysyl]-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-C


RN 187147-06-4 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N-[[[3-[[4-(.alpha.-D-
 mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-
 lysyl]-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A





PAGE 1-B


L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-C

OH

RN 187284-57-7 CAPLUS
CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-((alpha-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 28 OF 37 USPATFULL
ACCESSION NUMBER: 96.99296 USPATFULL
TITLE: Peptide-Chelator conjugates
INVENTOR(S): Goodbody, Anne, Toronto, Canada
Pollak, Alfred, Toronto, Canada
PATENT ASSIGNEE(S): Resolution Pharmaceuticals Inc., Mississauga, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5569745		19961029
APPLICATION INFO:	US 1994-202178		19940225 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
ASSISTANT EXAMINER:	Prickril, Benet		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	557		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Peptide-chelator conjugates are provided that when labelled with a traceable metal are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin while the chelator component serves as a labelling site for metals, in particular radionuclide metals such as technetium-99m.

IT 169048-14-ODP, chelates
(peptide-chelator conjugates for diagnostic imaging)

RN 169048-14-0 USPATFULL
CN L-Alanine, N-[6-[2-[S-[(acetylaminomethyl)-N-[N-(2-pyridinylcarbonyl)-L-seryl]-L-cysteinyl]hydrazino]-N-[N2-[1-[1-[N2-(N-formyl-L-threonyl)-L-lysyl]-L-prolyl]-L-arginyl]glycyl]-L-norleucyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 28 OF 37 USPATFULL (Continued)

PAGE 1-B



L5 ANSWER 29 OF 37 USPATFULL

ACCESSION NUMBER: 96:12706 USPATFULL
TITLE: Diagnostic and therapeutic compositions and methods for

INVENTOR(S): Chiknas, Steven G., Vienna, VA, United States
PATENT ASSIGNEE(S): Carbaugh, Jr., John E., Rosslyn, VA, United States
(U.S. individual)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 5490981	19960213
APPLICATION INFO.:	US 1994-234602	19940428 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-866358, filed on 6 Jul 1993, now abandoned which is a continuation of Ser.	
No.		

US 1992-832994, filed on 10 Feb 1992, now abandoned
which is a division of Ser. No. US 1990-619525, filed
on 29 Nov 1990, now abandoned

DOCUMENT TYPE: Misc 1990, now abandoned
FILE SEGMENT: Utility
PRIMARY EXAMINER: Granted
LEGAL REPRESENTATIVE: Kim, Kay K. A.
NUMBER OF CLAIMS: Wenderoth, Lind & Ponack
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1362

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides which present an epitope substantially similar to the activation site region epitope of apolipoprotein(a) are provided. Antibodies raised against such peptides bind to apolipoprotein(a). Such antibodies and peptides, as well as peptide constructs for immunization are provided. Also provided are monoclonal antibodies and hybridomas, polyclonal serum, assays, diagnostic systems in kit form, chromatographic methods and materials, and synthetic secondary standards. Therapeutic compositions and methods are also provided.

IT 116925-44-1D, resin-bound
(carrier core sequence of, apolipoprotein(a). activation-site
region-derived peptide construct for antibody prodn. in relation to)


region-derived pept
RN 116925-44-1 USPATFULL

RN 116945-44-1 USPAIFULL
 CN .beta.-Alanine,
 N-[N2,N6-bis[N2,N6-bis[N2,N6-bis[N-(N-glycylglycyl)glycyl]-
 L-lysyl]-L-lysyl]-L-lysyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 29 OF 37 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B



L5 ANSWER 29 OF 37 USPATFULL (Continued)

PAGE 1-C



L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:49205 CAPLUS

DOCUMENT NUMBER: 126:171890

TITLE: Macromolecular recognition: effect of multivalency in the inhibition of binding of yeast mannan to concanavalin A and pea lectins by mannosylated dendrimers

AUTHOR(S): Page, Daniel; Zanini, Diana; Roy, Rene
CORPORATE SOURCE: Dep. of Chemistry, Univ. of Ottawa, Ottawa, ON, K1N 6N5, Can.

SOURCE: Bioorganic & Medicinal Chemistry (1996), 4(11), 1949-1961
CODEN: BMCECP; ISSN: 0968-0896

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal

LANGUAGE: English
AB The synthesis and binding properties of a new family of high affinity .alpha.-D-mannopyranoside ligands are described. The synthesis of the new multivalent ligands is based on the scaffolding of multiantennary branches of L-lysine residues having electrophilic N-chloroacetylated end groups as core structures. An .alpha.-D-mannopyranoside with p-substituted aryl aglycon ending with a thiol group was prepd. and covalently attached to each of the branches of the dendritic structures. The resulting glycodendrimers with 2, 4, 8, and 16 mannoside residues were tested for their relative inhibitory potency by solid-phase enzyme-linked lectin assays (ELLA) using Me and p-nitrophenyl .alpha.-D-mannopyranosides as stds. Concns. necessary for 50% inhibition (IC50's) of binding of yeast mannan to Jack bean phytohemagglutinin (Conavalia ensiformis, Con A) and to pea lectin (Pisum sativum) were detd.

Analogous mannosylated copolyacrylamides were also prepd. for comparison. The IC50 values were also plotted as a function of dendrimer valences. The inhibitions showed that the 16-mer was approx. 600- and 2000-fold more potent than Me .alpha.-D-mannopyranoside, and 66- and 1383-fold more potent than p-nitrophenyl .alpha.-D-mannopyranosides with Con A and pea lectins, resp. Even when these nos. are expressed relative to single mannosylated residues per dendrimers, the relative potencies against the arom. mannoside are still 4- and 86-fold better against Con A and pea lectins. These results unequivocally indicate that the optimum inhibitory binding properties of the new mannosylated dendrimers vary with both dendrimer and lectin valences.

IT 187147-04-2P 187147-06-4P 187284-57-7P
187284-90-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(prepn. of mannosylated dendritic glycopeptides and their effect on binding of yeast mannan to Con A and pea lectins)
RN 187147-04-2 CAPLUS
CN .beta.-Alanine, N2,N6-bis[N-[[[3-[[4-(.alpha.-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B




RN 187147-06-4 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N-[[[3-[[4-(.alpha.-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-C

RN 187284-57-7 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-(.alpha.-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 187284-90-8 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-(.alpha.-D-mannopyranosyloxy)phenyl]amino]-3-oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)


L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 IT 155679-65-5 155679-66-6 107284-53-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of mannopyranosyl dendritic glycopeptides and their effect on
 binding of yeast mannan to Con A and pea lectins)
 RN 155679-65-5 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N-(chloroacetyl)glycylglycyl]-L-lysyl]-
 L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 155679-66-6 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N-(chloroacetyl)glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C

CH₂Cl

||
O

RN 187284-53-3 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N2,N6-bis[N-(chloroacetyl)glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl]-L-lysyl- (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 IT 187147-03-1P 187147-05-3P 187284-72-6P
 187284-91-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of mannopyranosyl dendritic glycopeptides and their effect on
 binding of yeast mannan to Con A and pea lectins)

RN 187147-03-1 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N-[[[3-oxo-3-[[[4-[(2,3,4,6-tetra-O-acetyl-
 .alpha.-D-mannopyranosyl)oxy]phenyl]amino]propyl]thio]acetyl]glycylglycyl]-
 L-lysyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B




RN 187147-05-3 CAPLUS
 CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N2,N6-bis[N2,N6-bis[N-(chloroacetyl)glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***



RN 187284-91-9 CAPLUS

CN .beta.-Alanine, N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-
 [(2,3,4,6-tetra-O-acetyl-.alpha.-D-mannopyranosyl)oxy]phenyl]amino]-3-
 oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl]-L-lysyl-
 (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A



PAGE 2-C

RN 187284-72-6 CAPLUS

CN .beta.-Alanine,

N2,N6-bis[N2,N6-bis[N2,N6-bis[N-[[[3-[[4-[(2,3,4,6-tetra-O-
 acetyl-.alpha.-D-mannopyranosyl)oxy]phenyl]amino]-3-
 oxopropyl]thio]acetyl]glycylglycyl]-L-lysyl]-L-lysyl]-L-lysyl-
 (9CI) (CA INDEX NAME)

L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1996:148250 CAPLUS

DOCUMENT NUMBER:

124:197208

TITLE:

Thrombus Imaging Using Technetium-99m-Labeled High Potency GPIIb/IIIa Receptor Antagonists. Chemistry

and

Initial Biological Studies

AUTHOR(S):

Pearson, Daniel A.; Lister-James, John; McBride, William J.; Wilson, David M.; Martel, Lawrence J.; Civitello, Edgar R.; Dean, Richard T.

CORPORATE SOURCE:

Department of Chemistry, Diotech Inc., Londonderry, NH, 03053, USA

SOURCE:

Journal of Medicinal Chemistry (1996), 39(7), 1372-82

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB

Platelet-specific compds. which are radiolabeled with .gamma.-emitting radionuclides may be particularly useful for the noninvasive in vivo detection of thrombi. The synthesis of peptides which are potent inhibitors of platelet aggregation and which contain a chelator for the radionuclide technetium-99m are described. The target compds. were designed such that stable, oxotechnetium(V) species could be prep'd. where the site of metal coordination was well defined. A strategy was employed where the pharmacophore -Arg-Gly-Asp- (RGD), or RGD mimetic, was constrained in a ring which was formed by the S-alkylation of a cysteine residue with an N-terminal chloroacetyl group. Binding affinities were enhanced by the replacement of arginine with the arginine mimetics S-(3-aminopropyl)cysteine and 4-aminophenylalanine. Further enhancements could be obtained by the synthesis of oligomers which contained two or more rings contg. receptor binding regions. The increase

in binding affinity seen was more than that expected from a simple stoichiometric increase of pharmacophore. The most potent compds. described had IC50s of approx. 0.03 .mu.M for the inhibition of human platelet aggregation, which is comparable to the most potent fibrinogen antagonists reported to date. Two of the more potent peptides (P280 and P748) were labeled with technetium-99m and assessed in a canine thrombosis model. The 99mTc complexes of the peptides prep'd. in this work should hold promise to serve as useful thrombus imaging agents due to their high receptor binding affinity, ease in prep'n., and expected rapid pharmacokinetics.


IT

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (SPECT of thrombus using 99mTc-labeled GPIIb/IIIa receptor antagonists: chem. and initial biol. studies)


RN 173963-88-7 CAPLUS

CN .beta.-Alaninamide, N6-[N2,N6-bis[N-(mercaptoacetyl)-D-tyrosyl-S-(3-aminopropyl)-L-cysteinylglycyl]-L-.alpha.-aspartyl-L-cysteinyl-L-lysylglycylglycyl]-L-lysyl]-L-lysylglycyl-L-cysteinyl-, cyclic (1.fwdarw.5), (1'.fwdarw.5')-bis(thioether) (9CI) (CA INDEX NAME)

PAGE 1-C



PAGE 2-A



L5. ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1786687-718 CAPLUS
CN Glycinamide, L-cysteinyglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-
  prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-
  prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-lysyl-L-
  threonyglycyl-L-lysyl-L-prolylglycyl-L-leucyl-L-asparaginyglycyl-L-
  glutaminy-L-lysylglycyl-L-glutaminy-L-lysylglycyl-L-alpha-glutamyl-L-

```

lylyglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-
(1.fwdarw.1'''), (1'.fwdarw.1'''), (1''.fwdarw.1'''))-tris(thioether)
with
N2,N6-bis[N-(mercaptoacetyl)-L-beta.-alanyl-L-beta.-alanyl]-N6-[N-(mercaptoacetyl)-L-beta.-alanyl-L-beta.-alanyl]-L-lysyl-6-amino-hexanoyl-N6-[6-(15-[4S,4S,6R]-hexahydro-2-oxo-1H-thiazolo[3,4-d]imidazol-4-yl)-1-, oxopentyl]amino]-3-oxohexyl-L-lycyl-L-tyrosinamide (9C1)
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 178668-72-9 CAPLUS
CN Glycinamide, L-cysteinyglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-threonyglycyl-L-isyl-L-leucyl-L-asparaginyglycyl-L-glutaminyl-L-lysylglycyl-L-glutaminyl-L-alanylglucyl-L-alpha.-glutamyl-L-

lyeylgylcyl-L-prolyl-(4R)-4-hydroxy-L-prolylgylcyl-L-prolyl-(4R)-4-hydroxy-L-prolylgylcyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-
(1,fwdarw,1''), (1',fwdarw,1''), (1'',fwdarw,1''')-tris(thioether)
With
N2,N6-bis[N-(mercaptoacetyl)-.beta.-.alanyl-.beta.-.alanyl-L-lysyl-N6-[N-(mercaptoacetyl)-.beta.-.alanyl-.beta.-.alanyl-L-lysyl-6-aminohexanoyl-N6-[6-[5-(3as,4s,6R)-hexahydro-2-oxo-1H-thiazio[3,4-d]imidazo[4-y]-1-oxopentyl-mercapto-1-oxohexyl]-L-lysyl-L-tyrosinamide (9C1) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:155533 CAPLUS

DOCUMENT NUMBER: 124:212160

TITLE: Monoamine, diamide, thiol-containing metal chelating agents

INVENTOR(S): McBride, William; Deen, Richard T.

PATENT ASSIGNEE(S): Diatech, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 44

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533497	A1	19951214	WO 1995-US6914	19950601
W:	AU, BR, CA, CN, JP, KR			
CA 2191951	AA	19951214	CA 1995-2191951	19950601
AU 9526944	A1	19960104	AU 1995-26944	19950601
AU 707040	B2	19990701		
BR 9507917	A	19970812	BR 1995-7917	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
CN 1093424	B	20021030		
EP 804252	A2	19971105	EP 1995-922159	19950601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
JP 10501531	T2	19980210	JP 1995-501181	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602
PRIORITY APPLN. INFO.:			US 1994-253973	A 19940603
			WO 1995-US6914	W 19950601

OTHER SOURCE(S):

MARPAT 124:212160

AB The invention relates to reagents useful in prepg. radiolabeled diagnostic

and therapeutic agents (radiopharmaceuticals). Specifically, the invention provides such reagents that are monoamine, diamide, and thiol-contg. metal chelators. Methods of making such reagents, and methods of using the radiopharmaceuticals produced therefrom are also provided.

IT 174350-40-4DP, technetium 99 complexes 174350-58-4DP,

technetium 99 complexes

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(monoamine, diamide, and thiol-contg. metal chelating agents

as radiopharmaceuticals)

RN 174350-40-4 CAPLUS

CN L-Cysteinamide, N6-[N2,N6-bis[N-(mercaptoacetyl)-D-tyrosyl-S-(3-


aminopropyl)-L-cysteinyglycyl-L-.alpha.-aspartyl-L-cysteinyglycylglycyl-

L-cysteinyglycylglycyl-L-lysyl]-L-lysylglycyl-, cyclic


(1'.fwdarw.5), (1'.fwdarw.5')-bis(thioether) (9CI) (CA INDEX NAME)

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B




L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 1-D



PAGE 2-A



RN 174350-58-4 CAPLUS

CN L-Cysteinamide,


N6-[N2,N6-bis[N-[N-(N-acetyl-L-threonyl)-L-lysyl]-L-

prolyl]glycylglycyl-L-lysyl]-L-lysylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



IT 174350-40-4P 174350-58-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(monoamine, diamide, and thiol-contg. metal chelating agents

as radiopharmaceuticals)

RN 174350-40-4 CAPLUS

CN L-Cysteinamide, N6-[N2,N6-bis[N-(mercaptoacetyl)-D-tyrosyl-S-(3-


aminopropyl)-L-cysteinyglycyl-L-.alpha.-aspartyl-L-cysteinyglycylglycyl-

L-cysteinyglycylglycyl-L-lysyl]-L-lysylglycyl-, cyclic


(1'.fwdarw.5), (1'.fwdarw.5')-bis(thioether) (9CI) (CA INDEX NAME)

L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B


L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
prolyl]glycyl]glycyl]-L-lysyl]-L-lysyl]glycyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-C



PAGE 1-D



PAGE 2-A

RN 174350-58-4 CAPLUS
CN L-Cysteinamide,
N6-[N2,N6-bis[N-[N-[1-[N2-(N-acetyl-L-threonyl)-L-lysyl]-L-

L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:858801 CAPLUS
DOCUMENT NUMBER: 123:250205
TITLE: Peptide-chelator conjugates for diagnostic imaging
INVENTOR(S): Goodbody, Anne; Pollek, Alfred
PATENT ASSIGNEE(S): Resolution Pharmaceuticals Inc., Can.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9522996	A2	19950831		
WO 9522996	A3	19951012	WO 1995-CA106	19950224
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5569745	A	19961029	US 1994-202178	19940225
CA 2182670	AA	19950831	CA 1995-2182670	19950224
AU 9518033	A1	19950911	AU 1995-18033	19950224
EP 746340	A1	19961211	EP 1995-909606	19950224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LT, LU, MC, NL, PT, SE				
JP 09509419	T2	19970922	JP 1995-522045	19950224
US 5679642	A	19971021	US 1996-713484	19960913
US 5865544	A	19990202	US 1997-955263	19971021
PRIORITY APPLN. INFO.: US 1994-202178 19940225				
WO 1995-CA106 19950224				
US 1996-713484 19960913				

OTHER SOURCE(S): MARPAT 123:250205
AB Peptide-chelator conjugates are provided that, when labeled with a traceable metal, are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin, while the chelator component serves as a labeling site for metals, in particular radionuclide metals such as ^{99m}Tc. Thus, i.m. zymosan-induced inflammation in rats was visualized by scintigraphy with i.v. injected, ^{99m}Tc-labeled N,N-dimethylglycyl-Ser-acetamidomethylcysteiny-Gly-Thr-Gln-Pro-Arg. The inflamed muscle contained 0.070% of the administered radioactivity per


g after 30 min, and the ratio of radioactivity in inflamed vs. uninflamed muscle was 5.0. In the above peptide, N-dimethylglycyl-Ser-acetamidomethylcysteine represents the chelating moiety, and Thr-Gln-Pro-Arg is the tuftsin analog moiety.

IT 169048-14-0DDP, chelates
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide-chelator conjugates for diagnostic imaging)


RN 169048-14-0 CAPLUS
CN L-Alanine, N-[6-[2-[S-[(acetylamino)methyl]-N-[N-(2-pyridinylcarbonyl)-L-seryl]-L-cysteinyl]hydrazino]-N-[N-[N2-[1-[1-[N2-(N-formyl-L-threonyl)-L-lysyl]-L-prolyl]-L-arginyl]glycyl]-L-norleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



```

RN      160818-36-0 CAPLUS
CN      Glycine, N-[N6-[[[[(6-amino-2-[[N-(N-acetyl-L-leucyl)-L-
        leucyl]amino]hexyldiene)amino]oxy]acetyl]-N2-[N6-[[[[(6-amino-2-[[N-(N-
        acetyl-L-leucyl)-L-leucyl]amino]hexyldiene)amino]oxy]acetyl]-N2-[N6-[[[[(6-
        amino-2-[[N-(N-acetyl-L-leucyl)-L-leucyl]amino]hexyldiene)amino]oxy]acetyl
        ]-N2-[N6-[[[[(6-amino-2-[[N-(N-acetyl-L-leucyl)-L-
        leucyl]amino]hexyldiene)amino]oxy]acetyl]-N2-[N6-[[[[(6-amino-2-[[N-(N-
        acetyl-L-leucyl)-L-leucyl]amino]hexyldiene)amino]oxy]acetyl]-N2-[N-(N-[N-
        [[[(6-amino-2-[[N-(N-acetyl-L-leucyl)-L-leucyl]amino]hexyldiene)amino]oxy]
        acetyl)]glycyl]]glycyl]]glycyl]-L-leuyl]-L-lseryl]-L-lseryl]-L-lseryl]-L-lseryl]-
        L-stereoisomer [SC], (CA INDEX NAME)

```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9425071	A1	19941110	WO 1994-1B93	19940505
	AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, HU, JP, LU, NL, NO, PL, RO, RU, US			
RM: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 6001364	A	19991214	US 1993-105904	19930831
US 6174530	B1	20010116	US 1993-114787	19930831
EP 678981	A1	19960228	EP 1994-913192	19940505
EP 678981	B1	20000329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE	JP 08510210	T2	19961029	JP 1994-524080	19940505
	AU 686153	B2	19980205	AU 1994-65438	19940505
	AT 191148	E	20000415	AT 1994-913192	19940505
	US 6217873	B1	20010417	US 1993-537928	19960105
PRIORITY APPLN. INFO.:				US 1993-57594	A 19930505
				US 1993-105904	A 19930831
				US 1993-114877	A 19930831
				WO 1994-1893	W 19940505

WO 1994-1B93 W 19940505
AB Provided by this invention are essentially homogeneous, defined compns.
of matter and hetero-polyoximes of defined structure comprising a baseplate
structure having a plurality of oxime bonds, wherein each oxime bond

links a specifically active mol. (e.g., a bioactive peptide) to the baseplate. Also provided are novel baseplates having a plurality of oxime-forming complementary reactive groups and novel specifically reactive mols.

having a oxime-forming complementary reactive group. Addnl., methods are described for prepg. these novel compns. by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active mol. Pharmaceutical compns. contg. these polyoximes and methods

of inducing an immune response or of imaging cells with the polyoximes are claimed. Baseplate structures contg. aminoxyacetyl (AQA) or glyoxylyl (GLX) reactive groups and peptides with complementary reactivity, i.e., peptides contg. GLX or AQA termini, were prep'd. The polyoximes were formed by reaction of the baseplates and peptide deriva.

IT 14081-36-OP

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptide-contg. polyoximes for use as pharmaceuticals and

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323425	A1	19931125	WO 1993-CA207	19930507

CA 2094785 AA 19931109 CA 1993-2094785 19930423

PRIORITY APPLN. INFO.: US 1992-880691 19920508
AB A branched peptide carrying a no. of chelating groups (metal chelating peptide (MCP)) has a C-terminus that may be structured to provide a variety of means for unidirectional coupling to a targeting agent such as an antibody. The no. of metal chelating sites may be quite large (in excess of 16). The MCP can be used to deliver a compound.

radiionuclides to a target cell by coupling the MCP to a targeting agent. A branched peptide with a C-terminal .beta.-alanine was synthesized by t-Boc chem. with branches introduced by coupling to .epsilonpsilon.-amino groups of lysine and EDTA moieties added as the t-Bu protected deriv. Methods for coupling the protein to antibodies via the carbohydrate moiety using a maleimide are discussed.

IT 154531-07-4
RL: BIOL (Biological study)
(as metal chelating peptide for targetted delivery of metal radionuclides)

RN 154531-07-4 CAPLUS

CN .beta.-Alanine, N-[N-[N-[N2,N6-bis[N2,N6-bis[N2,N6-bis(N-[N-[2-(
 (bis(carboxymethyl)amino)ethyl]-N-(carboxymethyl)glycyl]glycyl]-D-lysyl]-D-
 lysyl]-D-lysyl]-D-tyrosyl]-D-alanyl]-D-cysteiny]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 154531-08-SD, derivs. with coupling reagents
RL: BIOL (Biological study)
(as metal chelating peptide for targetted delivery of metal
radionuclides, conjugation with targetting moieties)

CN .beta.-Alanine, N-([N2-[N-[N-[N2,N6-bis([N2,N6-bis([N2,N6-bis([N-[N-[2-

(bis(carboxymethyl)amino)ethyl]-N-(carboxymethyl)glycyl]glycyl]-D-lysyl]-D-lysyl]-D-lysyl]-D-tyrosyl]-D-alanyl]-D-lysyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as metal chelating peptide for targetted delivery
 of metal radionuclides)

LS ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:263042 CAPLUS
DOCUMENT NUMBER: 120:263042
TITLE: DNA transporter system and its use for genetic transformation and gene therapy
INVENTOR(S): Smith, Louis C.; Woo, Savio L. C.
PATENT ASSIGNEE(S): Baylor College of Medicine, USA
SOURCE: PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318759	A1	19930930	WO 1993-US2725	19930319
W:	AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GR, HU, JP, LU, NL, NO, PL, RO, RU, SE, UA, US			
RN:	AT, BE, CH, DE, DK, ES, FR, GB, IT, NL			
AU 9339668	A1	19931021	AU 1993-39668	19930319
AU 671450	B2	19960829		
EP 632722	A1	19950111	EP 1993-909155	19930319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			
SE				
JP 07505283	T2	19950615	JP 1993-516812	19930319
US 6033884	A	20000307	US 1993-167641	19931214
US 5994109	A	19991130	US 1995-460890	19950603
US 6150168	A	20001121	US 1995-460971	19950605
US 6177554	B1	20010123	US 1995-462040	19950605
PRIORITY APPLN. INFO.:			US 1992-855389	A 19920320
			WO 1993-US2725	A 19930319
			US 1993-167641	A3 19931214

AB A DNA transporter system capable of non-covalently binding to DNA and facilitating the insertion of the DNA into a cell is described. The DNA transporter system includes a binding complex which non-covalently binds the DNA. The binding complex includes a mol. that is capable of non-covalently binding to the DNA and being covalently linked to a surface ligand and to a nuclear ligand. The surface ligand is capable of binding to a cell surface receptor and the nuclear ligand is capable of recognizing and transporting the transporter system through the nuclear membrane. A plurality of these binding complexes are attached to the DNA to facilitate the transport of the DNA into the cell. Addnl., a third binding complex which includes a virus can also be non-covalently linked to the DNA. The virus facilitates the movement of the DNA through the cytoplasm and into the nucleus. Also described are a variety of structures which can be used as part of the transporter system as well as methods of using the transporter system to introduce DNA into cells. A modified oligonucleotide designed to target SV40 vectors to specific cells and then to the nucleus of the targeted cell was prepd. The oligonucleotide, which was linked to an intercalating dye, comprised thymine and 5-Me cytosine. Attached via linkers were ligands for cell surface receptors and nuclear localization peptides.

LS ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
IT 154531-22-39
RL: PREP (Preparation)
(prepn. of, for use in DNA transporter system for genetic transformation and gene therapy)
RN 154531-22-3 CAPLUS
CN L-Lysine, N-[1-oxo-3-[[2-[[[L-tyrosyl-N6-[26-[[[4-O-.beta.-D-galactopyranosyl-.beta.-D-glucopyranosyl]oxy]-14-[[[6-[[[2-[[[4-O-.beta.-D-galactopyranosyl-.beta.-D-glucopyranosyl]oxy]-1,1-bis[[[4-O-.beta.-D-galactopyranosyl-.beta.-D-glucopyranosyl]oxy)methyl]ethyl]amino]-6-oxohexyl]amino]carbonyl]-25,25-bis[[[4-O-.beta.-D-galactopyranosyl-.beta.-D-glucopyranosyl]oxy)methyl]-1,4,12,16,23-penta-oxo-8,9-dithia-5,13,17,24-tetraazahexacos-1-yl]-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl]amino]ethyl]dithio]propyl]-L-tyrosyl-N6-(3-carboxy-1-oxopropyl)-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-L-lysyl-L-alanyl-, (11.fwdarw.1')-amide with glycyl-L-tyrosyl-L-seryl-L-threonyl-L-prolyl-L-prolyl-L-lysyl-L-lysyl-L-lysyl-L-arginyl-L-lysyl-L-valyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-prolinamide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***